Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 8/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329900 | 0.92 | C5AR1 (0.41) | C5AR1FGFR4 | |
| SCHEMBL1330250 | 0.90 | MRGPRX4 (0.40) | C5AR1MRGPRX4LMNAHPGDMAPT | |
| SCHEMBL1329407 | 0.88 | C5AR1 (0.38) | C5AR1KDM4EHPGDPOLBMAPT | |
| SCHEMBL1328471 | 0.88 | C5AR1 (0.39) | C5AR1KDM4EHPGDMAPT | |
| SCHEMBL1328429 | 0.88 | POLB (0.45) | C5AR1MRGPRX4LMNAKDM4EHPGD | |
| SCHEMBL1330106 | 0.87 | C5AR1 (0.42) | C5AR1LMNAHPGDPOLBMAPT | |
| SCHEMBL1328305 | 0.87 | MRGPRX4 (0.42) | C5AR1MRGPRX4LMNAKDM4EHPGD | |
| SCHEMBL1328398 | 0.87 | C5AR1 (0.37) | C5AR1MRGPRX4NR1H4 | |
| SCHEMBL1329519 | 0.87 | C5AR1 (0.38) | C5AR1LMNAKDM4EHPGDFGFR4 | |
| SCHEMBL1328473 | 0.86 | C5AR1 (0.38) | C5AR1LMNAHPGDFGFR4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | claimed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885MRGPRX4 30/4885LMNA 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.